Metabolex signs global development and license agreement with OMJPI

Jun 22 2010NewsGuard 100/100 Score

Metabolex, Inc. announced today that they have entered into a global development and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) to further develop and discover compounds for the treatment of type 2 diabetes and other disorders. Under the agreement, OMJPI will receive an exclusive worldwide license to develop, manufacture, and commercialize several Metabolex programs that are currently at the preclinical stage.

Under the terms of the agreement, Metabolex will receive an upfront payment and could be eligible to receive development, regulatory, and commercial milestones up to $330 million.  Metabolex is also eligible to receive royalties on worldwide sales of marketed products.

"We look forward to this partnership and to maximizing the significant potential of Metabolex's programs to bring first-in-class therapies to patients with type 2 diabetes and other disorders," said Harold Van Wart, Ph.D., President and Chief Executive Officer of Metabolex.

Source:

Metabolex, Inc.

Posted in:

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options
Diabetes rates skyrocket globally with millions left untreated
Diabetes medication shows promise in reducing alcohol use
Comparing camel, cow, and goat milk: Which is best for diabetes and heart health?
Spermidine regulates RIPK1 to combat diabetes and vascular damage
SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients
Study reveals slower fat gain in babies exposed to gestational diabetes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Global diabetes cases exceed 800 million highlighting urgent need for action